Moore, A M <br/><br/>
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  Apr 2006 
 - 93-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0169-5002 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2005.12.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Carcinoma, Small Cell--drug therapy<br/>Drug Resistance, Neoplasm<br/>Female<br/>Gefitinib<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Quinazolines--therapeutic use<br/>Survival Rate<br/>Treatment Outcome